Impact of sodium–glucose cotransporter-2 inhibitors on heart failure outcomes in cancer patients and survivors: a systematic review and meta-analysis - Summary - MDSpire
Advertisement
Impact of sodium–glucose cotransporter-2 inhibitors on heart failure outcomes in cancer patients and survivors: a systematic review and meta-analysis
To evaluate the impact of SGLT2 inhibitors on heart failure outcomes in cancer patients and survivors, focusing on both HF hospitalization and new HF diagnoses.
Key Findings:
SGLT2i reduced HF hospitalizations by 51% (RR 0.49, 95% CI 0.36-0.66, I² = 28%, P < 0.01).
SGLT2i reduced new HF diagnoses by 71% (RR 0.29, 95% CI 0.10–0.87, I² = 71%).
Among breast cancer patients on anthracyclines, HF hospitalization risk was reduced by 99% (RR 0.0085, P = 0.0081).
Interpretation:
SGLT2 inhibitors significantly lower the risk of HF hospitalization and new HF diagnoses among cancer patients, especially in those receiving anthracycline chemotherapy.
Limitations:
The review is limited to studies available up to June 2024, and potential bias in study selection may affect results.
Further prospective trials are needed to confirm findings and explore integration into cancer management.
Conclusion:
SGLT2 inhibitors may help protect the heart during and after cancer treatment, particularly for breast cancer patients on anthracyclines, warranting further research to validate these findings.
